Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogeneic bone marrow transplantation

Blood

Volumn 95, Issue 2, 2000, Pages 404-409

  Chomel, Jean Claude ^b   Brizard, Françoise ^b   Veinstein, Anne ^b   Rivet, Jérôme ^b   Sadoun, Alain ^b   Kitzis, Alain ^a   Guilhot, François ^b   Brizard, André ^b  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYTARABINE; HYDROXYUREA; RECOMBINANT ALPHA INTERFERON;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REMISSION;

EID: 0034650993     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.404     Document Type: Article

References (33)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497-1501.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99.
4. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-554.
5. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069-3081.
6. Brizard F, Chomel JC, Veinstein A, et al. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon α therapy? Leukemia. 1998;12:1076-1080.
7. Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myelogenous leukemia. Blood. 1998;92:2315-2321.
8. Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myelogenous leukemia. Blood. 1998;91:3357-3365.
9. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
10. Guilhot F, Chastang C, Michallet M, et al. (for the French Chronic Myeloid Leukemia Study Group). Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223-229.
11. Guilhot F, Dreyfus B, Brizard A, Huret JL, Tanzer J. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside. Leuk Lymphoma. 1991;4:49-55.
12. Guilhot F, Guerci A, Fière D, et al. The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rationale and design of the French trials. Bone Marrow Transplant. 1996; 17(suppl 3):S29-S31.
13. Gratwohl A, Hermans J, Goldman JM, et al. (for the Chronic Leukemia Working Parry of the European Group for Blood and Marrow Transplantation). Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087-1092.
14. Grossman A, Silver RT, Szatroswki TP, Gutfriend A, Verma RS, Benn PA. Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia. 1991;5:540-547.
15. Hochhaus A, Lin F, Reiter A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood. 1996; 87:1549-1555.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
17. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993; 82:1929-1936.
18. Patri S, Dascalescu C, Chomel JC, et al. Monitoring and prognostic evaluation of sex-mismatched bone marrow transplantation by competitive PCR on Y chromosome sequences. Bone Marrow Transplant. 1996;17:625-632.
19. Kirk JA, Reems JA, Roecklein BA, et al. Benign marrow progenitors are enriched in the CD34+/ HLA-DR1o population but not in the CD34+/ CD381o population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization. Blood. 1995;86:737-743.
20. Verfaillie CM, Bhatia R, Miller W, et al. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood. 1996;87:4770-4779.
21. Bedi A, Zehnbauer BA, Collector MI, et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood. 1993;81:2898-2902.
22. Leemhuis T, Leibowitz D, Cox G, et al. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood. 1993;81:801-807.
23. Keating A, Wang XH, Laraya R Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood. 1994;83:1744-1749.
24. Yin JL, Williams BG, Arthur CK, Ma DDF. Interferon response in chronic myeloid leukaemia correlated with ABUBCR expression: a preliminary study. Br J Haematol. 1995;89:539-545.
25. El-Rifai W, Ruutu T, Vettenranta K, Temtamy S, Knuutila S. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a metaphase-FISH study. Br J Haematol. 1996;92:365-369.
26. Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood. 1996;88:1796-1802.
27. Lengyel P. Tumor-suppressor genes: news about the interferon connection. Proc Natl Acad Sci U S A. 1993;90:5893-5895.
28. Shirodkar S, Ewen M, DeCaprio JA, Morgan J, Livingston DM, Chitteriden T. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 1992;68:157-166.
29. Faderl S, Talpaz T, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 1999;93:2755-2759.
30. Uhr JW, Scheuermann RH, Street N, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med. 1997;3:505-509.
31. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse with T-cell depletion. Ann Intern Med. 1988; 108:806-814.
32. Sacchi S, Kantarjian H, Cohen P, Pierce S, Talpaz M. Immune-mediated and unusual complications during alpha-interferon therapy in chronic myelogenous leukemia. J Clin Oncol. 1995;13:2401-2407.
33. Oka T, Sastry KJ, Nehete P, et al. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia. 1998;12:155-163.